Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PLAU | P00749 | 2/20 | 0.56 |
| ▸ | MASP2 | O00187 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.54 |
| ▸ | F2 | P00734 | 4/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | F12 | P00748 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204318 | 0.97 | LMNA (0.59) | LMNAPLAUMASP2THPOPRSS1 | |
| Hydrochloric Acid SCHEMBL982825 | 0.95 | PRSS1 (0.61) | LMNAPLAUMASP2THPOPRSS1 | |
| Hydrochloric Acid SCHEMBL9338860 | 0.92 | LMNA (0.54) | LMNAPLAUMASP2THPOPRSS1 | |
| SCHEMBL27438192 | 0.90 | WDR5 (0.64) | LMNAPLAUMASP2THPOPRSS1 | |
| Benzamidine SCHEMBL428760 | 0.88 | F2 (0.73) | LMNAPLAUMASP2THPOPRSS1 | |
| Hydrochloric Acid SCHEMBL9391856 | 0.88 | WDR5 (0.61) | LMNAPLAUMASP2THPOPRSS1 | |
| SCHEMBL537030 | 0.83 | LMNA (0.77) | LMNAPLAUMASP2THPOPRSS1 | |
| Hydrochloric Acid SCHEMBL392375 | 0.80 | PRSS1 (0.78) | LMNAPLAUMASP2THPOPRSS1 | |
| Hydrochloric Acid SCHEMBL30999366 | 0.80 | PRSS1 (0.78) | LMNAPLAUMASP2THPOPRSS1 | |
| SCHEMBL32662891 | 0.75 | PLAU (0.64) | PLAUPRSS1F2F10F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202243-B2 | Substituted imidazotriazines | BAYER HEALTHCARE AG (DE) | 2007-04-10 | — | — | US | disclosed |
| US-20060166993-A1 | Substituted imidazotriazines | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1599479-A1 | SUBSTITUTED IMIDAZOTRIAZINES | Bayer HealthCare AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6936609-B2 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1404677-A1 | IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2004005290-A1 | SUBSTITUTED IMIDAZOTRIAZINES | BAYER HEALTHCARE AG (DE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003000693-A1 | IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| US-3940395-A | CNS DEPRESSANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166993-A1 | Substituted imidazotriazines | SNCA, PARK7, TPMT | LMNA 3545/4885PLAU 4740/4885MASP2 3505/4885 |
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | PDE3A, PDE2A, PDE4A | LMNA 2027/4885PLAU 1661/4885MASP2 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.